FETAL AND NEONATAL MONITORING MARKET ANALYSIS

Fetal and Neonatal Monitoring Market, by Product Type (Fetal Monitoring Devices (Heart Rate Monitors, Uterine Contraction Monitors, Pulse Oximeters, and Others (Fetal ECG, Doppler, and Continuous Monitors)) and Neonatal Monitoring Devices (Cardiac Monitors, Capnographs, Blood Pressure Monitors, Pulse Oximeters, and Others (X-ray, CT Scans, and MRI))), by Portability (Portable Monitoring Devices and Non-portable Monitoring Devices), by Method (Invasive Monitoring Devices, and Non-Invasive Monitoring Devices), by End User (Hospitals, Nursing Homes, Specialty Clinics, and Ambulatory Surgery Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Jun 2020
Code : CMI1319
Pages :184
Formats :
Excel and PDF
Industry : Medical Devices

Market Challenges And Opportunities

Fetal and Neonatal Monitoring Market - Restraints

The major restraining factor for the fetal and neonatal monitoring market include product recalls by the regulatory bodies. The product recalls arise due to product failure, component inconsistency, and packaging problems. For instance, in October 2019, the U.S. FDA recalled the Mindray DS USA, Inc.’s (a subsidiary of Mindray Medical International Limited) Rosie4 Vital Signs Monitor, which is used for monitoring physiologic parameters, including Pulse Oximetry (SpO2), Pulse Rate (PR), Non-invasive Blood Pressure (NIBP), Temperature (TEMP), and Carbon Dioxide (CO2) on adult, pediatric, and neonatal patients in professional healthcare facilities. The product was recalled by the U.S. FDA because the NIBM valve system was not included in the marketing clearance. The company initiated the recall but not all products were corrected or removed.